IGF1 and amyotrophic lateral sclerosis: However, intramuscular- or intrathecal administration of IGF-1 had no significant effect on disease progression of SOD1G93A mice [29], and subcutaneous IGF-1 has not shown benefit in 2-year ALS trial [30].